PURPOSE: To evaluate the in vitro efficacy of several anti-staphylococcal agents against a nationwide collection of contemporary @entity794 clinical isolates from several healthcare centres in Greece. METHODS: Thirty hospitals throughout Greece (18 in Attica) provided all clinical isolates of @entity794 from April 2012 to May 2013 to a central lab to be re-submitted to susceptibility testing. The MICs were evaluated by Vitek   2 with the exception of @entity40629 (OXOID M.I.C. Evaluator   ). @entity2176 and @entity13757 MICs were also evaluated by Etest  . Heterogeneously @entity2176 -intermediate strains ( @entity20637 ) were detected by the Etest   GRD. @entity20637 phenotype was confirmed by PAP-AUC. RESULTS: A total of 1005 isolates (39% @entity794 ) were studied. Susceptibility rates were: @entity2929 66.5%, @entity3402 79.2%, SXT 98.9%, @entity1215 97.3%, @entity12119 67%, @entity3477 78.8%, @entity2176 99.9%, @entity40629 92.9% and linezolid, @entity9001 and @entity13757 100%. For @entity23782 , high level resistance could be excluded for 98.9% of isolates. @entity2176 Etest   MIC50/90 were 1.5/1.5   mg/L, 58.5% of isolates exhibited a MIC   >   1 and 8.7% a MIC of 2   mg/L, while Vitek   MIC50/90 were 1/1 and 3.1% showed MIC   >   1   mg/L. One @entity20637 strain was detected. Among the selected 175 isolates that were screened for @entity20637 phenotype, six (3.4%) were positive. In 315 bloodstream isolates, 64.1% had a @entity2176 Etest   MIC   >   1   mg/L. CONCLUSIONS: This multi-centre surveillance study revealed that a significant percentage of contemporary @entity794 isolates from Greek @entity1 have a @entity2176 MIC (>   1   mg/L) that may compromise the clinical efficacy of the drug for the treatment of serious infections. The in vitro activity of SXT, @entity1215 , @entity23782 , @entity5136 , @entity9001 , @entity13757 and @entity40629 remains excellent.

Nationwide surveillance of resistance rates of XXXX clinical isolates from Greek hospitals, 2012-2013.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity20637 :: ('57506', 'Gene') :: ['hVISA', 'VISA'] @entity2176 :: ('MESH:D014640', 'Chemical') :: ['vancomycin', 'Vancomycin'] @entity3477 :: ('MESH:C104727', 'Chemical') :: ['moxifloxacin'] @entity12119 :: ('MESH:D005672', 'Chemical') :: ['fusidic acid'] @entity40629 :: ('MESH:C490727', 'Chemical') :: ['ceftaroline'] @entity2929 :: ('MESH:D004917', 'Chemical') :: ['erythromycin'] @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus', 'MRSA', 'S.aureus'] @entity23782 :: ('MESH:D016712', 'Chemical') :: ['mupirocin'] @entity13757 :: ('MESH:D017576', 'Chemical') :: ['daptomycin'] @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampicin'] @entity5136 :: ('MESH:C098010', 'Chemical') :: ['linezolid'] @entity9001 :: ('MESH:C119092', 'Chemical') :: ['tigecycline'] @entity3402 :: ('MESH:D002981', 'Chemical') :: ['clindamycin']
@entity794 :: (1280,Species) :: ['Staphylococcus aureus']
